Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematologic malignancies: Initial Results from multi-institutional first-in-human trials

Rita Assi, Amer Beitinjaneh, Emily Hopewell, Christina Vaughan, Sumeet Bhatia, Allie Carter, Jennifer Schwartz, Malak Khalife, Simpla Mahato, Lionel Apetoh, Huda Salman

Blood (2025) 146 (Supplement 1): 5947.

https://doi.org/10.1182/blood-2025-5947

Published: 2025

Journal Articles

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Sairah Ahmed, Jinwen Cao, Matthew Mei, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Mohamed Iburahim Haja Maideen, Omnia Farahat, Adam Braun, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2025-1844

Published: 2025

Journal Articles

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

Sarah Nikiforow, Kris Mahadeo, Sridhar Chaganti, Amer Beitinjaneh, Sylvain Choquet, Daan Dierickx, Armin Ghobadi, Roberta Valenti, Anke Friedetzky, Sandrine Roye, Ran Reshef, Susan Prockop, Robert Baiocchi

Blood (2025) 146 (Supplement 1): 1934.

https://doi.org/10.1182/blood-2025-1934

Published: 2025

Journal Articles

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Sairah Ahmed, Matthew Mei, Jinwen Cao, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Omnia Farahat, Mohamed Iburahim Haja Maideen, Adam Braun, Daniel Reef, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 5938.

https://doi.org/10.1182/blood-2025-5938

Published: 2025

Journal Articles

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Amer Beitinjaneh, Supriya Gupta, Fateeha Furqan, John Baird, Wen-Kai Weng, Caron Jacobson, Soyoung Kim, Zhongyu Feng, Babatunde Adedokun, Jiali Yan, Qian Huang, Kenny Hu, Timothy Best, Ioana Kloos, Grace Lee, Mehdi Hamadani, Marcelo Pasquini, Frederick Locke

Blood (2025) 146 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2025-3606

Published: 2025

Journal Articles

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Blood (2025) 146 (Supplement 1): 4537.

https://doi.org/10.1182/blood-2025-4537

Published: 2025

Journal Articles

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 1009.

https://doi.org/10.1182/blood-2025-1009

Published: 2025

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Idelalisib (Zydelig®) Maintenance in B-Cell Non-Hodgkin's Lymphoma after High Dose Chemotherapy and Autologous Stem Cell Transplantation

Jean A. Yared, Tanmay Singh, Amer Beitinjaneh, Aaron P. Rapoport, Saurabh Dahiya, Djordje Atanackovic, Nancy M. Hardy, Mehmet H. Kocoglu, Tara Toth, Deanna Pineiro, Olga Goloubeva

Blood (2024) 144 (Supplement 1): 6354.

https://doi.org/10.1182/blood-2024-199596

Published: 2024

Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Blood (2024) 144 (Supplement 1): 4388.

https://doi.org/10.1182/blood-2024-198018

Published: 2024

Journal Articles

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Blood (2023) 142 (Supplement 1): 107.

https://doi.org/10.1182/blood-2023-179269

Published: 2023

Journal Articles

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Matthew Mei, Sairah Ahmed, Amer Beitinjaneh, Natalie S. Grover, Carlos A. Ramos, Khong Bee Kang, Paul I. Nadler, Aung Myo, Ivan D. Horak, Helen E. Heslop

Blood (2022) 140 (Supplement 1): 12728–12730.

https://doi.org/10.1182/blood-2022-157131

Published: 2022

Journal Articles

New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV + PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Kris Michael Mahadeo, Robert A. Baiocchi, Amer Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Laurence Gamelin, Armin Ghobadi, Norma Guzman-Becerra, Manher Joshi, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Wei Ye, Susan Prockop

Blood (2022) 140 (Supplement 1): 10374–10376.

https://doi.org/10.1182/blood-2022-157766

Published: 2022

Journal Articles

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Blood (2022) 139 (9): 1330–1339.

https://doi.org/10.1182/blood.2021013289

Published: 2022

Includes: Supplemental data

Journal Articles

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Susan Prockop, Kris Michael Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi

Blood (2021) 138 (Supplement 1): 301.

https://doi.org/10.1182/blood-2021-147274

Published: 2021

Journal Articles

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Antonio M. Jimenez, Miguel-Angel Perales, Sean M Devlin, Lazaros J. Lekakis, Craig S. Sauter, Denise Pereira, Amer Beitinjaneh, Samantha Brown, Trent Wang, Doris M Ponce, Mark S. Goodman, Stephanie Chinapen, Krishna V. Komanduri, Brian C Shaffer

Blood (2021) 138 (Supplement 1): 1814.

https://doi.org/10.1182/blood-2021-150714

Published: 2021

Journal Articles

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Blood (2021) 138 (Supplement 1): 744.

https://doi.org/10.1182/blood-2021-147563

Published: 2021

Journal Articles

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

Blood (2021) 137 (23): 3291–3305.

https://doi.org/10.1182/blood.2020009362

Published: 2021

Includes: Supplemental data

Journal Articles

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2020) 136 (Supplement 1): 20–22.

https://doi.org/10.1182/blood-2020-136382

Published: 2020

Journal Articles

Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis

Juan Pablo Alderuccio, MD, Russ A Kuker, MD, Priscila Barreto-Coelho, MD, Bianca Marie Martinez, BS, Feng Miao, MS, Amer Beitinjaneh, MD MPH, MSc, Trent Peng Wang, DO, Isildinha M Reis, PhD, Izidore S. Lossos, MD, Craig H. Moskowitz, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-141098

Published: 2020

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Feasibility and tolerability of a CD4 re-directed chimeric antigen receptor T cell therapy (CD4CAR) in hematologic malignancies: Initial Results from multi-institutional first-in-human trials

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Subgroup analysis based on prior treatment from the Phase 3 allele study of tabelecleucel for epstein-barr virus-driven post-transplant lymphoproliferative disease

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Real-world effectiveness and safety outcomes by age, comorbidities, and frailty among relapsed or refractory (R/R) Mantle Cell Lymphoma (MCL) patients treated with brexucabtagene autoleucel (brexu-cel)

Real-world survival outcomes following allogeneic hematopoietic cell transplantation in peripheral T-cell lymphomas: A Florida multi-institutional cohort study

Mosunetuzumab and polatuzumab combined with axicabtagene ciloleucel induce high complete response rates at day+90 in Relapsed/Refractory large B-cell lymphoma

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Idelalisib (Zydelig®) Maintenance in B-Cell Non-Hodgkin's Lymphoma after High Dose Chemotherapy and Autologous Stem Cell Transplantation

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Real-World Outcomes of Brexucabtagene Autoleucel (Brexu-cel) for Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL): A CIBMTR Subgroup Analysis of High-Risk Characteristics

Phase 1b/2 Study of Autologous CD30.CAR-T Cells in Combination with Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma after Failure of Frontline Therapy (ACTION)

Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission

Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Post-Transplant Cyclophosphamide Is Associated with Improved Clinical Outcomes in HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real World Experience from the US Lymphoma CAR T Consortium

Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis

One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Prognostic Value of PET/CT Metrics in Patients with Relapsed and Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Platinum-Based Chemotherapy: An Intent-to-Treat Analysis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only